NCT00028301已完成3 期
A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)
Bristol-Myers Squibb147 个研究点 分布在 4 个国家开始时间: 2001年2月最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 147
研究概览
简要总结
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
详细描述
The study is designed to determine the metabolic changes, antiviral activity, safety, and tolerability of atazanavir as compared to LPV/RTV, each in combination with 2 nucleosides, over the initial 24 weeks, with a final analysis at 48 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (147)
Loading locations...
相似试验
已完成
3 期
A Study to Compare Two Anti-HIV Drug CombinationsHIV InfectionsNCT00002447Hoffmann-La Roche146
已完成
4 期
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With AtriplaHIV-1NCT02547844Hospital Universitari Vall d'Hebron Research Institute30
已完成
不适用
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIVHIV InfectionsNCT00006441National Institute of Allergy and Infectious Diseases (NIAID)398
终止
2 期
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected PatientsHIV InfectionsNCT00122577French National Agency for Research on AIDS and Viral Hepatitis50
已完成
3 期
The Late Presenter Treatment Optimisation StudyHIV/AIDSNCT03696160NEAT ID Foundation447